Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neupogen in pediatric liver cirrhosis
NCT04113317Phase 3Completed
- Sponsor
- Faculty of Medicine, Universitas Indonesia
- Start
- Jan 2020
- Primary completion
- Feb 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim in Liver cirrhosis (LC), sponsored by Faculty of Medicine, Universitas Indonesia. Primary endpoints: Pediatric End-stage Liver Disease at 90 days and Anthropometric Changes at 90 days. Started Jan 2020; status: completed.
02
Drugs
filgrastim
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT04113317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113317.